NASDAQ:RNA

Avidity Biosciences (RNA) Stock Price, News & Analysis

Avidity Biosciences logo
$6.48 +0.05 (+0.78%)
As of 11/17/2026 04:00 PM Eastern

About Avidity Biosciences Stock (NASDAQ:RNA)

Advanced

Key Stats

Today's Range
$6.45
▼
$6.95
50-Day Range
$6.43
▼
$10.51
52-Week Range
$6.36
▼
$16.77
Volume
352,108 shs
Average Volume
229,349 shs
Market Capitalization
$139.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.00
Consensus Rating
Moderate Buy

Company Overview

Avidity Biosciences is a biotechnology company focused on developing RNA-based medicines for diseases that affect muscle. Its Antibody Oligonucleotide Conjugate (AOC) platform combines antibodies with oligonucleotides to help deliver RNA-targeting treatments into muscle cells.

The company’s research and clinical pipeline has included programs for neuromuscular disorders such as myotonic dystrophy type 1 and Duchenne muscular dystrophy. Avidity was founded in 2012 and is based in San Diego, California.

AI Generated. May Contain Errors.

Avidity Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

RNA MarketRank™: 
2.64721556088 of 5 stars

Avidity Biosciences scored higher than 53% of companies evaluated by MarketBeat, and ranked 601st out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Avidity Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 1 strong buy rating, 4 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Avidity Biosciences has a consensus price target of $33.00, representing about 409.3% upside from its current price of $6.48.

  • Amount of Analyst Coverage

    Avidity Biosciences has only been the subject of 3 research reports in the past 90 days.

  • Read more about Avidity Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Avidity Biosciences are expected to decrease in the coming year, from ($3.56) to ($5.60) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Avidity Biosciences is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Avidity Biosciences is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Avidity Biosciences has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    21.91% of the float of Avidity Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Avidity Biosciences has a short interest ratio ("days to cover") of 16.07, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Avidity Biosciences has recently increased by 0.61%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Avidity Biosciences does not currently pay a dividend.

  • Dividend Growth

    Avidity Biosciences does not have a long track record of dividend growth.

  • News Sentiment

    Avidity Biosciences has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Avidity Biosciences this week, compared to 2 articles on an average week.
  • Search Interest

    Only 3 people have searched for RNA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
Receive RNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RNA Stock News Headlines

Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
Avidity Biosciences (RNA) Expected to Post Earnings on Thursday
See More Headlines

RNA Stock Analysis - Frequently Asked Questions

Avidity Biosciences' stock was trading at $72.13 at the beginning of the year. Since then, RNA shares have decreased by 91.0% and is now trading at $6.48.

Avidity Biosciences, Inc. (NASDAQ:RNA) released its earnings results on Thursday, November, 12th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.56. The biotechnology company earned $15.32 million during the quarter, compared to analyst estimates of $15 million.

Avidity Biosciences (RNA) raised $216 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 14,400,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO.

Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Avidity Biosciences investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Tesla (TSLA), Taiwan Semiconductor Manufacturing (TSM), Precision BioSciences (DTIL) and Editas Medicine (EDIT).

Company Calendar

Last Earnings
11/12/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:RNA
CIK
1599901
Fax
N/A
Employees
190
Year Founded
2013

Price Target and Rating

High Price Target
$72.00
Low Price Target
$15.00
Potential Upside/Downside
+409.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.46
Quick Ratio
10.46

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.50 per share
Price / Book
0.68

Miscellaneous

Outstanding Shares
21,570,000
Free Float
N/A
Market Cap
$139.77 million
Optionable
Optionable
Beta
N/A

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NASDAQ:RNA) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners